登录 | 注册    关注公众号  
搜索
 > 【CD4】

CD4信息

英文名称:T-cell surface antigen CD4
中文名称:T细胞表面抗原CD4
靶点别称:CD4mut,CD4 Antigens,T-cell surface antigen T4/Leu-3,T-cell surface glycoprotein CD4,CD4,CD4 Molecule,CD4 Antigen (P55),CD4 Receptor,CD4 Antigen
上市药物数量:1
临床药物数量:23
最高研发阶段:批准上市

CD4 分子别名

CD4,CD4mut,LEU3

CD4 分子背景

Cluster of Differentiation 4 (CD4) is also known as T-cell surface antigen T4/Leu-3 (LEU-3) and CD4mut, is a single-pass type I  membrane glycoprotein,and is a member of the immunoglobulin superfamily. CD4 expressed on the surface of T helper cells, monocytes, macrophages, and dendritic cells. It has four immunoglobulin domains (D1 to D4) that are exposed on the extracellular surface of the cell: D1 and D3 resemble immunoglobulin variable (IgV) domains. D2 and D4 resemble immunoglobulin constant (IgC) domains. CD4 is a co-receptor that assists the T cell receptor (TCR) with an antigen-presenting cell. Using its portion that resides inside the T cell, CD4 amplifies the signal generated by the TCR by recruiting an enzyme, known as the tyrosine kinase lck, which is essential for activating many molecules involved in the signaling cascade of an activated T cell. CD4 also interacts directly with MHC class II molecules on the surface of the antigen-presenting cell using its extracellular domain. The extracellular domain adopts an immunoglobulin-like beta-sandwich with seven strands in 2 beta sheets, in a Greek key topology. CD4 has also been shown to interact with SPG21, Lck and Protein unc-119 homolog. CD4 is a primary receptor used by HIV-1 to gain entry into host T cells. HIV infection leads to a progressive reduction of the number of T cells possessing CD4 receptors. Therefore, medical professionals refer to the CD4 count to decide when to begin treatment for HIV-infected patients.

CD4 前沿进展

CD4上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Ibalizumab Hu5A8; TMB-355; TNX-355; 5AB 批准上市 百健 特罗格佐, Trogarzo EU HIV感染 Theratechnologies Europe Ltd 2018-03-06 HIV感染 详情

CD4临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
IT-1208 (Kyowa Hakko Kirin) IT-1208 临床一期 协和发酵麒麟株式会社 肿瘤 详情
VRC-HIVAAV070-00-GT AAV8-VRC07 临床一期 National Institute Of Allergy And Infectious Diseases (Niaid) HIV感染 详情
T-allo-10 T-allo-10 临床一期 斯坦福大学 移植物抗宿主病 详情
CALRLong36 peptide (Herlev Hospital) 临床一期 Herlev Hospital 骨髓增生性疾病 详情
VRC-HIVMAB091-00-AB N6LS; Z258‐N6LS; VRC-HIVMAB091-00-AB 临床一期 National Institute Of Allergy And Infectious Diseases (Niaid) HIV感染 详情
ITV 1(Nonindustrial source) ITV-1 临床三期 Synexa Life Sciences, Immunotech Laboratories, Nonindustrial Source HIV感染 详情
CD4^LVFOXP3 Treg-like cell therapy CD4^LVFOXP3 临床一期 斯坦福大学 自身免疫性多内分泌腺病 详情
VRC-01-LS VRC-HIVMAB-080-00-AB; VRC-01-LS 临床二期 National Institute Of Allergy And Infectious Diseases (Niaid) HIV感染 详情
TMB-365 TMB-365 中裕新药股份有限公司 详情
Autologous Regulatory Т-cell Therapy Institute Of Biophysics And Cell Engineering Of National Academy Of Sciences Of Belarus 详情
SCRI-E2CAR_EGFRtv1 SCRI-E2CAR_EGFRtv1 Umoja BioPharma Inc 详情
IMCY-0141 IMCY-0141 Imcyse Sa 详情
HIV-1 peptide vaccine (microparticulate/monovalent, UBI) 联合生物医药公司 详情
Semzuvolimab dB4; UB-421; mAb-B4 临床三期 联合生物医药公司 HIV感染 详情
10E8.4/iMab (Aaron Diamond AIDS Research Center) TMB-370 临床一期 Aaron Diamond Aids Research Center For The City Of New York, Inc HIV感染 详情
MVA-EL MVA-EBNA1/LMP2 香港中文大学, Cancer Research Uk 详情
Tregalizumab hB-F5; BT-061 Biotest Pharma Gmbh 详情
Anti-CD4 CAR T-cell therapy (University of Pennsylvania) CAR-C34ZFN 宾夕法尼亚大学 详情
PRO-542 PRO-542 哥伦比亚大学 详情
GEN-009 GEN-009 Genocea Biosciences 详情
BG-8962 BG-8962 National Institute Of Allergy And Infectious Diseases (Niaid) 详情
LCAR-T2C CAR-T cell therapy (Nanjing Medical University) 南京医科大学附属第一医院 详情
RB-0003 RB-0003; BNT-111 Biontech Se, Tron 详情
Mosedipimod EC-18 Enzychem Lifesciences 详情
CD4 CAR T cell therapy (iCell Gene Therapeutics) 临床一期 归气丹生物医药(香港)有限公司 T-细胞淋巴瘤 详情
VRC-07-523 VRC-07-523-L S; VRC-HIVMAB075-00-AB; VRC-HIVMAB-075 -00-AB; VRC-07-523; TMB-380 临床二期 National Institute Of Allergy And Infectious Diseases (Niaid), 中裕新药股份有限公司 HIV感染, 获得性免疫缺损综合征, 逆转录病毒感染, 病毒性性传播疾病 详情
CD4-directed chimeric antigen receptor engineered T-cells (Stony Brook University) CD4CAR 临床一期 Stony Brook University School Of Medicine, 归气丹生物医药(香港)有限公司, 刘易斯维尔大学 T-细胞淋巴瘤, T-细胞白血病 详情

消息提示

请输入您的联系方式,再点击提交!

确定